• Je něco špatně v tomto záznamu ?

The prognostic reasoning system for chronic kidney disease progression (PROGRES-CKD) may help improve waiting list management for outpatient nephrology services in a second-level public hospital in Italy

P. Fabbrini, F. Pieruzzi, F. Bellocchio, R. Casana Eslava, J. Silvestre Llopis, K. Morillo Navarro, P. Ferraresi, L. Usvyat, J. Larkin, J. Rosemberg, S. Stuard, L. Neri

. 2025 ; 38 (4) : 1219-1227. [pub] 20250227

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015940

BACKGROUND: The management of patients with non-dialysis dependent chronic kidney disease (NDD-CKD) is challenging due to coexisting diseases, competing risks and uncertainties around optimal transition planning. Such clinical challenges are further exacerbated by physician shortage, coupled with rising service demands, which may hinder timely medical access due to long waiting times. Accurate progression risk assessment may help optimize resource allocation and adapting care based on individual patients' needs. This study validated the Prognostic Reasoning System for Chronic Kidney Disease Progression (PROGRES-CKD) in an Italian public hospital and compared its potential impact on waiting list optimization against physician-based protocols. METHODS: First we first validated PROGRES-CKD by assessing its accuracy in predicting kidney replacement therapy (KRT) initiation within 6 months and 24 months in a historical cohort of patients treated at the San Gerardo Hospital (Italy) between 01-01-2015 and 31-12-2019. In a second study we compared PROGRES-CKD to attending nephrologists' prognostic ratings and simulated their potential impact on a waiting list management protocol. RESULTS: We included 2005 patients who underwent 11,757 outpatient nephrology visits in 4 years. Most visits occurred for NDD-CKD stage 4 patients; the incidence of KRT onset was 10.8 and 9.32/100 patient-years at the 6 and 24-month prediction horizon cohorts, respectively. PROGRES-CKD demonstrated high accuracy in predicting KRT initiation at 6 and 24 months (AUROC = 0.88 and AUROC = 0.85, respectively). Nephrologists' prognostic performance was highly operator-dependent, albeit always significantly lower than PROGRES-CKD. In the simulation exercise, allocation based on PROGRES-CKD resulted in more follow-up visits for patients progressing to end-stage kidney disease (ESKD) and fewer visits for non-progressing patients, compared to allocation determined by nephrologists' prognosis. CONCLUSIONS: PROGRES-CKD showed high accuracy in a real-world application. Waiting list simulation suggests that PROGRES-CKD may enable more efficient allocation of resources.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015940
003      
CZ-PrNML
005      
20250731091353.0
007      
ta
008      
250708s2025 it f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40620-025-02222-8 $2 doi
035    __
$a (PubMed)40014297
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Fabbrini, Paolo $u Struttura Complessa Nefrologia e Dialisi ASST Nord Milano, Milan, Italy. paolo.fabbrini@gmail.com $u President of Lombardy Section of the Italian Society of Nephrology, Medical Director - Struttura Complessa di Nefrologia, ASST Nord Milano Ospedale Bassini, via Gorky 50, 20092, Cinisello Balsamo, MI, Italy. paolo.fabbrini@gmail.com
245    14
$a The prognostic reasoning system for chronic kidney disease progression (PROGRES-CKD) may help improve waiting list management for outpatient nephrology services in a second-level public hospital in Italy / $c P. Fabbrini, F. Pieruzzi, F. Bellocchio, R. Casana Eslava, J. Silvestre Llopis, K. Morillo Navarro, P. Ferraresi, L. Usvyat, J. Larkin, J. Rosemberg, S. Stuard, L. Neri
520    9_
$a BACKGROUND: The management of patients with non-dialysis dependent chronic kidney disease (NDD-CKD) is challenging due to coexisting diseases, competing risks and uncertainties around optimal transition planning. Such clinical challenges are further exacerbated by physician shortage, coupled with rising service demands, which may hinder timely medical access due to long waiting times. Accurate progression risk assessment may help optimize resource allocation and adapting care based on individual patients' needs. This study validated the Prognostic Reasoning System for Chronic Kidney Disease Progression (PROGRES-CKD) in an Italian public hospital and compared its potential impact on waiting list optimization against physician-based protocols. METHODS: First we first validated PROGRES-CKD by assessing its accuracy in predicting kidney replacement therapy (KRT) initiation within 6 months and 24 months in a historical cohort of patients treated at the San Gerardo Hospital (Italy) between 01-01-2015 and 31-12-2019. In a second study we compared PROGRES-CKD to attending nephrologists' prognostic ratings and simulated their potential impact on a waiting list management protocol. RESULTS: We included 2005 patients who underwent 11,757 outpatient nephrology visits in 4 years. Most visits occurred for NDD-CKD stage 4 patients; the incidence of KRT onset was 10.8 and 9.32/100 patient-years at the 6 and 24-month prediction horizon cohorts, respectively. PROGRES-CKD demonstrated high accuracy in predicting KRT initiation at 6 and 24 months (AUROC = 0.88 and AUROC = 0.85, respectively). Nephrologists' prognostic performance was highly operator-dependent, albeit always significantly lower than PROGRES-CKD. In the simulation exercise, allocation based on PROGRES-CKD resulted in more follow-up visits for patients progressing to end-stage kidney disease (ESKD) and fewer visits for non-progressing patients, compared to allocation determined by nephrologists' prognosis. CONCLUSIONS: PROGRES-CKD showed high accuracy in a real-world application. Waiting list simulation suggests that PROGRES-CKD may enable more efficient allocation of resources.
650    _2
$a lidé $7 D006801
650    12
$a seznamy čekatelů $7 D014850
650    _2
$a progrese nemoci $7 D018450
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a chronická renální insuficience $x terapie $x diagnóza $7 D051436
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nemocnice veřejné $7 D006779
650    _2
$a senioři $7 D000368
650    _2
$a prognóza $7 D011379
650    12
$a nefrologie $7 D009398
650    _2
$a hodnocení rizik $x metody $7 D018570
650    12
$a ambulantní péče $7 D000553
650    _2
$a náhrada funkce ledvin $x statistika a číselné údaje $7 D017582
650    _2
$a časové faktory $7 D013997
651    _2
$a Itálie $7 D007558
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Pieruzzi, Federico $u Nephrology and Dialysis Unit, ASST Monza San Gerardo Hospital, Monza, Italy $u Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
700    1_
$a Bellocchio, Francesco $u Data Science Division, EMEA, APAC, LATAM Regions - Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, Italia Spa, Crema, Italy
700    1_
$a Casana Eslava, Raul $u Santa Barbara Smart Health, GDTI, Fresenius Medical Care, Valencia, Spain
700    1_
$a Silvestre Llopis, Jordi $u Santa Barbara Smart Health, GDTI, Fresenius Medical Care, Valencia, Spain
700    1_
$a Morillo Navarro, Kevin $u Santa Barbara Smart Health, GDTI, Fresenius Medical Care, Valencia, Spain
700    1_
$a Ferraresi, Paola $u Marketing Department, Fresenius Medical Care, Italia Spa, Crema, Italy
700    1_
$a Usvyat, Len $u Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, Waltham, USA
700    1_
$a Larkin, John $u Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, Waltham, USA
700    1_
$a Rosemberg, Jaroslav $u FMC-Dialysis Services Slovakia, Bratislava, Slovakia $u Medical Faculty, University of PJ Safarik, Kosice, Slovakia $u Institute of Social Health at Palacký University Olomouc (OUSHI), Olomouc, Czech Republic
700    1_
$a Stuard, Stefano $u Global Medical Office, Clinical Affairs, CoE Clinical & Therapeutic Governance, Fresenius Medical Care Italia Spa, Crema, Italy
700    1_
$a Neri, Luca $u Data Science Division, EMEA, APAC, LATAM Regions - Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, Italia Spa, Crema, Italy
773    0_
$w MED00002821 $t JN. Journal of nephrology $x 1724-6059 $g Roč. 38, č. 4 (2025), s. 1219-1227
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40014297 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091348 $b ABA008
999    __
$a ok $b bmc $g 2366643 $s 1253065
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 38 $c 4 $d 1219-1227 $e 20250227 $i 1724-6059 $m JN. Journal of nephrology $n J Nephrol $x MED00002821
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace